UK-based pharmaceutical firm GlaxoSmithKline (GSK) and US-based healthcare firm Innoviva have reported positive headline results from a non-inferiority lung function study of relvar ellipta in patients with well-controlled asthma.

Relvar ellipta is a once-daily dual combination of inhaled corticosteroid fluticasone furoate and beta-2 agonist vilanterol in a single inhaler, the Ellipta.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The results showed that patients with well-controlled asthma were able to switch to the once-daily relvar ellipta 100/25 from the twice-daily seretide accuhaler 250/50 without any affect on their lung function.

Seretide accuhaler is a twice-daily dual combination of fluticasone propionate / salmeterol in the Accuhaler inhaler.

The randomised, double-blind, double-dummy European Medicines Agency (EMA) approved study was conducted at multiple centres in 12 countries.

“The patients administered with relvar ellipta were found to maintain a better lung function when compared to patients who were given seretide accuhaler.”

The study’s primary objective was to establish the non-inferiority of relvar ellipta 100/25 once-daily, when compared to seretide accuhaler 250/50 twice-daily in adult and adolescent subjects 12 years of age and older with persistent bronchial asthma.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The study endpoint was the change from baseline during clinic visit evening FEV1 (pre-brochodilator and pre-dose) at the end of the 24-week treatment period.

The patients administered with relvar ellipta were found to maintain a better lung function when compared to patients who were given seretide accuhaler.

The study also included a third treatment arm with fluticasone propionate (FP), inhaled corticosteroid monotherapy to identify the lung function difference between treatments.

The serious adverse events (SAEs) and adverse events (AEs) were found to be consistent with the safety profile of relvar ellipta that was determined through previous studies.

Relvar ellipta is currently indicated in Europe for the regular treatment of patients aged 12 and above with asthma.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact